Capital Fund Management S.A. Sells 171,694 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Capital Fund Management S.A. has reduced its stake in Edwards Lifesciences Corporation by 49.6%, selling 171,694 shares to hold a total of 174,297 shares valued at approximately $12.63 million.
• Institutional investors and hedge funds collectively own 79.46% of Edwards Lifesciences, with significant increases in positions from firms like Jennison Associates LLC and Brown Advisory Inc.
• Wall Street analysts show a positive outlook for Edwards Lifesciences, with multiple upgrades and a consensus price target of $85.90, reflecting a Moderate Buy rating.

Capital Fund Management S.A. lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 49.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 174,297 shares of the medical research company's stock after selling 171,694 shares during the period. Capital Fund Management S.A.'s holdings in Edwards Lifesciences were worth $12,633,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Erste Asset Management GmbH lifted its position in shares of Edwards Lifesciences by 1.7% during the 1st quarter. Erste Asset Management GmbH now owns 19,820 shares of the medical research company's stock valued at $1,405,000 after buying an additional 326 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. lifted its position in shares of Edwards Lifesciences by 21.8% during the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 182,269 shares of the medical research company's stock valued at $13,214,000 after buying an additional 32,673 shares during the last quarter. Financial Advisors Network Inc. lifted its position in shares of Edwards Lifesciences by 1.8% during the 1st quarter. Financial Advisors Network Inc. now owns 19,944 shares of the medical research company's stock valued at $1,446,000 after buying an additional 355 shares during the last quarter. Forefront Analytics LLC lifted its position in shares of Edwards Lifesciences by 54.1% during the 1st quarter. Forefront Analytics LLC now owns 4,971 shares of the medical research company's stock valued at $360,000 after buying an additional 1,745 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at $26,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded up $0.5950 on Friday, hitting $81.7550. The company's stock had a trading volume of 3,076,141 shares, compared to its average volume of 4,824,093. The company has a 50-day simple moving average of $77.58 and a 200 day simple moving average of $74.69. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The company has a market capitalization of $48.00 billion, a PE ratio of 11.76, a PEG ratio of 3.95 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter last year, the firm posted $0.70 EPS. The company's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on EW. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Citigroup reissued a "buy" rating and set a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, Truist Financial increased their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $85.90.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president owned 50,356 shares of the company's stock, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,584 shares of company stock valued at $1,897,762 in the last 90 days. Corporate insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.